ImaBiotech SAS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImaBiotech SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10626
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImaBiotech SAS (ImaBiotech) is a contract research organization that offers mass spectrometry imaging services. The organization’s software products include quantinetix and multimaging. It offers services such as biomarker discovery, consulting and training, screening studies, target engagement studies, pharmaco-kinetics and dynamics studies, MALDI imaging services and toxicology studies. ImaBiotech provides its MALDI imaging services to therapeutic areas such as central nervous system, dermatology and cosmetics, cardiovascular and metabolic diseases, gastroenterology and others. The organization’s consultancy and training services include cost and profitability, feasibility or protocol studies, MALDI imaging mass spectrometry platform installation, project design, data storage, instrumentation and IT and others. It has its operations in France and the US. ImaBiotech is headquartered in Loos, France.

ImaBiotech SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImaBiotech SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImaBiotech SAS, Medical Devices Deals, 2012 to YTD 2018 9
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ImaBiotech Raises US$1.37 Million In Venture Financing 11
Partnerships 12
ImaBiotech Enters into Agreement with Dermira 12
Galderma Enters into Agreement with ImaBiotech 13
ImaBiotech Enters Into Agreement With Genfit 14
ImaBiotech SAS – Key Competitors 15
ImaBiotech SAS – Key Employees 16
ImaBiotech SAS – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
ImaBiotech SAS, Pharmaceuticals & Healthcare, Key Facts 2
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImaBiotech SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImaBiotech SAS, Deals By Therapy Area, 2012 to YTD 2018 8
ImaBiotech SAS, Medical Devices Deals, 2012 to YTD 2018 9
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ImaBiotech Raises US$1.37 Million In Venture Financing 11
ImaBiotech Enters into Agreement with Dermira 12
Galderma Enters into Agreement with ImaBiotech 13
ImaBiotech Enters Into Agreement With Genfit 14
ImaBiotech SAS, Key Competitors 15
ImaBiotech SAS, Key Employees 16
ImaBiotech SAS, Subsidiaries 17

List of Figures
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImaBiotech SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImaBiotech SAS, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ImaBiotech SAS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Daiho Corporation
    Daiho Corporation - Strategy, SWOT and Corporate Finance Report Summary Daiho Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Johns Hopkins University:医療機器:M&Aディール及び事業提携情報
    Summary Johns Hopkins University (JHU) is a research university which offers undergraduate, graduate, master’s, and doctoral programs. It offers educational services in the areas of arts and sciences, engineering, business, medicine, nursing, public health, and advanced international studies. It als …
  • Sysmex Inostics GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Sysmex Inostics GmbH (Sysmex Inostics), formerly Inostics GmbH, a subsidiary of Sysmex Corp, is a molecular diagnostics company that offers blood-based cell-free tumor treatment solutions. The company offers services such as clinical trials, research and development, and testing for physicia …
  • Rum Group for Transportation & Tourism Investment:戦略・SWOT・企業財務分析
    Rum Group for Transportation & Tourism Investment - Strategy, SWOT and Corporate Finance Report Summary Rum Group for Transportation & Tourism Investment - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychia …
  • Abionic SA-医療機器分野:企業M&A・提携分析
    Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company offers products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE application for android, iPhone & iPad, and accessories. Its abioSCOPE in vitro tests are design …
  • Uniper SE (UN01):企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SeQuent Scientific Ltd (512529):企業の財務・戦略的SWOT分析
    Summary SeQuent Scientific Ltd (SeQuent) is a pharmaceutical company that develops and manufactures animal health API, life science and industrial products. The company offers products such as aciclovir sodium, albendazole, artemether, artesunate, amyl meta cresol, citicoline sodium and dihydroartem …
  • Cellnet Group Ltd (CLT):企業の財務・戦略的SWOT分析
    Cellnet Group Ltd (CLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • T2 Biosystems Inc (TTOO):企業の財務・戦略的SWOT分析
    Summary T2 Biosystems Inc (T2 Biosystems) is a provider of clinical diagnostic products in the field of in vitro diagnostics. The company’s T2 magnetic resonance technology allows direct detection in complex samples such as whole blood, serum, plasma, sputum and urine. T2 Biosystems offers T2HemoSta …
  • Bullfrog Power Inc.:電力:M&Aディール及び事業提携情報
    Summary Bullfrog Power Inc. (Bullfrog Power) is a provider of green energy. It offers renewable energy solutions that help businesses and houses in reducing their environmental impact. Bullfrog's product portfolio includes green electricity, green fuel and green natural gas. The company, through its …
  • Actelion Ltd:企業の戦略・SWOT・財務分析
    Actelion Ltd - Strategy, SWOT and Corporate Finance Report Summary Actelion Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析
    Summary Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of …
  • Harvard University:企業のM&A・事業提携・投資動向
    Harvard University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Harvard University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Petro Matad Ltd (MATD):企業の財務・戦略的SWOT分析
    Summary Petro Matad Ltd (Petro Matad) is an oil and gas company that develops and operates oil and gas exploration properties. The company’s upstream oil and gas exploration asset base includes Block IV, Block XX, and Block V. Its Block XX is located in the far eastern part of Mongolia producing oil …
  • Delaware North:企業の戦略・SWOT・財務分析
    Delaware North - Strategy, SWOT and Corporate Finance Report Summary Delaware North - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • MEDACTA International SA:製品パイプライン分析
    Summary MEDACTA International SA (MEDACTA) is a medical device company that offers orthopedic surgical equipment. The company conducts research, development, manufacturing and commercialization of orthopedic products, neurosurgical systems and instrumentation. It offers prosthetic solutions for hip, …
  • Far Eastone Telecommunications Co Ltd (4904):企業の財務・戦略的SWOT分析
    Far Eastone Telecommunications Co Ltd (4904) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Nattopharma ASA (NATTO):企業の財務・戦略的SWOT分析
    Summary Nattopharma ASA (Nattopharma) is a pharmaceutical company that develops and sells vitamin K2 for health care industries. The company's MenaQ7, a vitamin K2 as menaquinone-7 for bone and cardiovascular health and children’s health. Its MenaQ7 varieties are suitable for vegans and vegetarians, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆